CST-103 (Conkwest)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameCST-103 (Conkwest)
Drug Alias NameCD16-expressing NK92 cell-based therapy (NantKwest)NK-92.CD16.176VZRx-103NK-92-Fc
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFox Chase Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunitybio IncFox Chase Cancer Center
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A